Rezpegaldesleukin Demonstrates Durable Hair Regrowth Six Months After Treatment Cessation in Phase 2b Alopecia Areata Study
NKTR sits 82% above its 52-week low of $33.4.
Summary
Phase 2b data show rezpegaldesleukin's hair regrowth benefits persist and deepen for six months after stopping treatment, with Phase 3 trials advancing in both alopecia areata and atopic dermatitis.
Key Events · Product Development and Regulatory · NKTR
-
Durable Off-Treatment Hair Regrowth
Six months after stopping treatment, 63% of patients maintained SALT Score ≤20, and SALT Score ≤10 responses deepened from 7% at Week 52 to 19% off treatment.
-
Efficacy Independent of Episode Duration
A new subgroup analysis showed comparable SALT Score ≤20 responses in patients with current alopecia areata episode <4 years (29%) vs ≥4 years (30%).
-
Phase 3 ZENITH AA Trial Planned
An 850-patient Phase 3 study in severe-to-very-severe alopecia areata is set to initiate in early 2027, with SALT Score ≤20 at Week 52 as the primary endpoint.
-
Third Phase 3 AD Study Initiated
The ZENITH AD program expanded into treatment-experienced atopic dermatitis patients; REZOLVE-AD maintenance data showed EASI-100 responses increased from 4% to 22% with Q4W dosing.
Analysis · NKTR · Life Sciences
The 8-K reveals detailed Phase 2b REZOLVE-AA results showing that 63% of patients maintained SALT Score ≤20 responses six months after stopping treatment, while near-complete hair regrowth (SALT ≤10) nearly tripled from 7% to 19% off treatment. This durability profile is unprecedented for alopecia areata therapies and directly supports the Phase 3 ZENITH AA trial launching in early 2027. The data also validate less frequent maintenance dosing, which could improve the commercial profile. Against the backdrop of the recent $90 million jury verdict against Eli Lilly, this clinical momentum strengthens Nektar's position in dermatology.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36% of the 1040 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $60.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $33.40 to $109.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.